Hugel Expands Collaboration with Domestic Medical Professionals to Strengthen Market Leadership

"We will create global standards of academic competitiveness and a sustainable industry culture based on deep trust with domestic medical professionals," said Jang Doo-hyun, CEO of Hugel, reaffirming the company's commitment to strengthening its market leadership.

According to Hugel, the nationwide academic program 'H.E.L.F. ACT in Region' will be held four times this year, starting in Busan and continuing in Seoul, Incheon, and Daejeon. The first event, held on May 9 at the Signiel Hotel in Busan, was attended by about 50 medical professionals and was described by the company as a success.

Jang explained, "This academic program aims to support Korean medical professionals, who are at the forefront of promoting K-Aesthetic culture, and to share clinical value."

The 'H.E.L.F. ACT in Region' program goes beyond simple product education; it aims to maximize the safety and efficacy of procedures by sharing clinical experiences. It is designed to enhance understanding of Hugel's main product lines to improve practical application in the field.

At the Busan event on May 9, Dr. Choi Woo-sik from Lamar Clinic in Ulsan introduced approaches to facial skin improvement using the Biorezin Skin Booster HA. Additionally, Dr. Oh Wook from Meilin Clinic at The Hyundai Seoul shared unresolved concerns and challenges regarding filler and toxin procedures, engaging in in-depth discussions with attendees.

Hugel plans to hold additional events in Seoul, Incheon, and Daejeon in June, September, and December, respectively.

Meanwhile, Hugel reported record earnings in the first quarter of this year. According to their announcement, the consolidated revenue for Q1 reached 116.6 billion won, with an operating profit of 47.6 billion won, marking increases of 29.9% and 22.3%, respectively, compared to the same period last year.

This strong performance was driven by rapid growth in the global market. The combined overseas sales of their main products, botulinum toxin and fillers, reached 70.8 billion won, a 46% increase year-on-year. Notably, the company recorded approximately 21 billion won in sales growth in the four major markets: the United States, China, Europe, and Brazil.